Psychiatric treatment conducted via telemedicine versus in-person consultations in mood, anxiety and personality disorders: a protocol for a systematic review and meta-analysisArticle Published on 2022-09-282022-11-16 Journal: BMJ Open [Category] meta-analysis, [키워드] 95% CI adult psychiatry Anxiety APA approval assessment Bia calculate calculated Chi-square CINAHL comparable conducted COVID-19 COVID-19 pandemic cumulative data set development disorders dropout rate Effect Ethics Evidence heterogeneity include information technology Intervention Major mean difference Meta-analysis methodological outcomes participant Patient satisfaction platform Potential Primary outcome PROSPERO protocol Psychiatric Psychiatric disorders psychiatry PsycINFO randomised controlled trial Repository required risk risk of bia secondary outcome sensitivity analysis systematic review Telemedicine test for heterogeneity Treatment Web of Science widespread [DOI] 10.1136/bmjopen-2021-060690 PMC 바로가기
Effectiveness and safety of fibrinolytic therapy in critically ill patients with COVID-19 with ARDS: protocol for a prospective meta-analysisArticle Published on 2022-09-262022-11-16 Journal: BMJ Open [Category] meta-analysis, SARS, [키워드] acute respiratory distress anticoagulation ARDS bleeding disorder bleeding disorders & bleeding event clinical trial clinical trials Coagulopathies COVID-19 COVID-19 pandemic Critical care Critically ill patient Efficacy and safety eligibility criteria eligible Evidence fibrin deposit fibrinolytic FIVE Gas exchange identify IMPROVE include Intensive intensive & lung Meta-analysis microthrombi Mortality other organs outcome Oxygenation Patient patients patients with COVID-19 peer-reviewed performed PROSPERO protocol quantitative synthesis randomised controlled trial Registered Safety secondary outcome Standard of care syndrome therapy Trial ventilation/perfusion with COVID-19 [DOI] 10.1136/bmjopen-2022-063855 PMC 바로가기
Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled TrialArticle Published on 2022-09-162022-11-15 Journal: Nutrients [Category] SARS, 진단, [키워드] 25-hydroxyvitamin D 95% CI Acute respiratory infection adjusted hazard ratio antibody baseline blood sample BNT162b2 BNT162b2 Pfizer boost Breakthrough SARS-CoV-2 infection cellular response ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 Oxford–AstraZeneca circulating collected Concentration concentrations Controlled deficiency determine dose dried blood spot Effect Efficacy elevated Follow-up IFN-γ IgA IgG IgM influence interferon interferon gamma investigated mean difference neutralising antibody neutralising antibody titre of BNT162b2 offer participant Pfizer Protective randomised controlled randomised controlled trial reported response risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2 vaccine significantly supernatant titre titres vaccination venous Vitamin Vitamin D Vitamin D status vitamin D supplement Vitamin D supplementation Whole blood [DOI] 10.3390/nu14183821 PMC 바로가기
Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipientsArticle Published on 2022-09-152022-11-15 Journal: Trials [Category] SARS, 진단, [키워드] 1:1 binding domain Booster vaccine cell-mediated response clinical Controlled trial COVID COVID-19 COVID-19 vaccination COVID-19 vaccine death develop disease severity dose Effectiveness Efficacy ENhance hospitalisation humoral hypothesise IgG immune cell population immunological Immunosuppression IMPROVE include increased risk Intervention kidney transplant recipient kidney transplant recipients Kidney transplantation live SARS-CoV-2 Modification mTOR inhibitor multicentre neutralisation New outcome participant Prednisolone Primary outcome proportion Protective protective immunity public health randomised randomised controlled trial Rapamycin recipient reduce reduced regimen registry responses SARS-CoV-2 SARS-CoV-2 vaccine secondary serological Sirolimus Standard of care Study protocol Tolerability Trial vaccination Vaccine vaccine response virus [DOI] 10.1186/s13063-022-06634-w PMC 바로가기
A home-based, multidisciplinary liver optimisation programme for the first 28 days after an admission for acute-on-chronic liver failure (LivR well): a study protocol for a randomised controlled trialArticle Published on 2022-09-052022-10-05 Journal: Trials [Category] 임상, [키워드] 1:1 28-day mortality addition Admission Admissions Analysis Appendix 1 benefit Care changes in chronic chronic condition chronic disease chronic liver disease cirrhosis clinical Clinical improvement Clinicians Cohort conducted COVID-19 COVID-19 pandemic criteria disease evaluated exploratory subgroup analysis feasibility generalisability generate global healthcare Health Health Service health team healthcare Healthcare systems heart failure hospitalisation implementation implication include Interdisciplinary health team. interim analysis Intervention intervention arm liver Liver disease Melbourne, Australia Mortality mortality risk New outcome participant Patient performed Prevalence Primary outcome Quality of life randomisation randomised randomised controlled trial RCT readmission recruit recruited recruitment reduced reducing Registered Registration registry required resource rising robust Safe secondary severity small sample size social work Study protocol suggested Treatment Trial well WHO [DOI] 10.1186/s13063-022-06679-x PMC 바로가기 [Article Type] Article
Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical studyArticle Published on 2022-09-022022-10-04 Journal: Trials [Category] SARS, 임상, 진단, [키워드] 28-day mortality addition Affect Alpha approved assessment Blood changes chronic inflammatory disease clinical study clinical trial collected Course COVID-19 current therapy dose driven by Effectiveness ethics committee EudraCT Friedrich Schiller high mortality hyperinflammation IL-6 IMPROVE infections Infectious diseases infliximab International Laboratory molecular molecular diagnostics monoclonal antibody morbidity multicentre Open-label Patient patients with COVID-19 primary endpoint pro-inflammatory cytokine protocol randomised randomised controlled trial receive Registered Research respiratory respiratory infections resulting severe COVID-19 Standard of care systemic inflammatory the disease therapy TNF-α Treatment Trial university Urine [DOI] 10.1186/s13063-022-06566-5 PMC 바로가기 [Article Type] Article
An online breathing and wellbeing programme (ENO Breathe) for people with persistent symptoms following COVID-19: a parallel-group, single-blind, randomised controlled trialRandomized Controlled Trial Published on 2022-09-012022-10-04 Journal: The Lancet. Respiratory Medicine [Category] Fulltext, MERS, 임상, [키워드] 1:1 adverse event Analysis Anxiety approach approaches assigned Block randomisation breathlessness chronic obstructive clinically clinics complementary computer-generated conducted COVID COVID-19 eight element English Generalised anxiety disorder groups Health Imperial College London IMPROVE improvement individual intention-to-treat population Intervention Mental mental health MHC outcome measure parallel-group participant participated Patient physical potential participant Primary outcome pulmonary disease qualitative data randomisation randomised controlled trial Randomly recovering from COVID-19 recruited Registered reported Research researcher responses responsible secondary secondary outcome single-blind statistically significant Symptom thematic analysis treatment group Trial unique usual care usual care group Visual Analogue Scale was done were excluded were given [DOI] 10.1016/S2213-2600(22)00125-4 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial말라위에서 9개월에서 12세 사이의 어린이를 대상으로 한 장티푸스 접합 백신의 안전성 및 면역원성: 이중 맹검, 무작위 대조 시험의 중첩 하위 연구Clinical Trial Published on 2022-09-012022-09-12 Journal: The Lancet. Global health [Category] Fulltext, MERS, 살모넬라증, 임상, 진단, [키워드] 1:1 95% CI adverse event age analysed antibody assigned baseline children chronic health conditions clinical trial COVID-19 double-blind eight eligible eligible participant ELISA enrolled evaluated Evidence foundation geometric mean titre HIV IgG Immunosuppression intention-to-treat population intramuscularly Local Melinda Gate occurred outcomes participant Phase 3 provide public health randomised controlled trial Randomly reactogenicity receive recipient recipients Registered remained Safety screened titre Tolerability Trial typhoid fever vaccination Vaccine was collected [DOI] 10.1016/S2214-109X(22)00275-3 PMC 바로가기 [Article Type] Clinical Trial
The short-term effect of a myofascial protocol versus light touch applied to the cervical spine towards the prevention of balance disorders in the elderly: protocol of a randomised controlled trialArticle Published on 2022-08-312022-10-05 Journal: Chiropractic & manual therapies [Category] SARS, 임상, [키워드] applied balance balance disorder battery Cervical cervical spine concerning Consequences COVID demonstrated double-blind Effect effective elderly evaluator experiment experimental group Gait group Health Inclusion influence Intervention knowledge lower limb lower limbs manual Mobility muscle Myofascial Myofascial release Neck Non-invasive occur Older adults Pain pandemic parameter Patient performance physical physiological Placebo placebo group prevention protection protocol Psychological randomised controlled trial Randomized receive recruitment reduce risk spine strength Strength. subject the placebo group Therapeutic treatment therapy trauma Treatment Variability [DOI] 10.1186/s12998-022-00446-0 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial중국에서 4가 스플릿-비리온 비활성화 인플루엔자 백신 및 23가 폐렴구균 다당류 백신과 함께 투여된 비활성화 SARS-CoV-2 백신(Sinopharm BBIBP-CorV)의 면역원성 및 안전성: 다기관, 비열등성, 공개 라벨, 무작위, 통제, 4상 시험Clinical Trial Published on 2022-08-262022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 23-valent pneumococcal polysaccharide vaccine Administered antibody assigned BBIBP-CorV block randomization blood sample China Coadministration Community dose eligible GMC GMT GMT ratio had no IgG antibody immunogenicity inactivated Inactivated SARS-CoV-2 vaccine individual Influenza Influenza virus multicentre non-inferiority Open-label participant per-protocol population pneumococcal Pneumonia polysaccharide polysaccharide vaccine randomised randomised controlled trial Randomly recruited Registered Safe SARS-CoV-2 SARS-CoV-2 neutralising antibody SARS-CoV-2 vaccine seroconversion rate serotypes Sinopharm Split-virion inactivated influenza vaccine. strain stratified Streptococcus pneumoniae the SARS-CoV-2 three group Trial vaccination Vaccine vaccine group [DOI] 10.1016/j.vaccine.2022.07.033 PMC 바로가기 [Article Type] Clinical Trial